证券代码：002250 证券简称：联化科技 公告编号：2025-049 联化科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （1）现场会议时间：2025年10月28日15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年10月28日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为2025年10月28日9:15至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025年10月21日 7、出席对象： （1）截至2025年10月21日下午收市时在中国证券登记结算公司深圳分公司 登记在册的公司全体股东均有权以本通知公布的方式出席本次股东会，及参加表 决；股东因故不能亲自到会，可书面委托代理人（该代理人不必是公司股东）出 席会议和参加表决； 1、股东会届次：2025年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开 ...

Core Insights - Company is actively developing and collaborating with major domestic clients, focusing on innovative drug development and has a pipeline of clinically promising products in phases II and III [1] - The global CXO service market is projected to grow from approximately $79.4 billion in 2024 to $161.6 billion by 2031, with a CAGR of 10.9% from 2025 to 2031 [1] - Company has established itself as a significant competitor in the CRDMO sector, providing comprehensive services from drug discovery to commercialization [1] Financial Performance - In the first half of 2025, the company's pharmaceutical business revenue reached 1.018 billion yuan, a year-on-year increase of 42.8%, with a gross margin of 42.75% [2] - The company has successfully completed multiple key validation projects, laying a solid foundation for capacity and technology [2] R&D and Technological Advancements - Company has expanded its R&D capabilities beyond traditional small molecules to include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides, enhancing its market responsiveness [3] - In 2024, the company developed 12 tubular process projects, with 7 achieving continuous production delivery [2][3] - The CRO segment has built capabilities in various technologies, including PROTAC, linker synthesis, and enzyme catalysis, to meet diverse client needs [2][3] Strategic Partnerships and Market Position - Company has deepened R&D collaborations with two global pharmaceutical leaders and partnered with multiple domestic innovative drug companies [2][4] - As a leading provider in the CDMO market for crop protection, the company has established strategic partnerships with five major original research crop protection companies [4] - The company has identified several products with commercialization potential within 3-5 years, supporting long-term business growth [4] Industry Outlook - The company is well-positioned to capitalize on the ongoing recovery in the pharmaceutical R&D and production industry, aiming to strengthen its position in the CXO value chain [5]

Core Viewpoint - The company has established cooperation and close connections with several leading enterprises in the new energy sector, including battery manufacturers and electrolyte manufacturers [1] Group 1 - The company is actively engaging with top enterprises in the new energy industry [1] - Collaboration includes partnerships with both battery and electrolyte manufacturers [1]

证券日报网讯联化科技（002250）9月25日在互动平台回答投资者提问时表示，医药业务上半年度增长 显著，主要系集中发货所致。目前，公司医药事业部已与一批国内外优质客户建立稳定商业联系，业务 合作覆盖范围持续扩大。公司跟随客户业务管线布局公司产品管线，未来随着公司与客户业务的不断深 入，客户专利期内产品的持续推广，公司医药业务将能继续实现增长。 ...

Group 1 - Company Lianhua Technology announced that on September 24, 2025, it will be participating in a research meeting hosted by Galaxy Securities, with senior vice president and secretary Chen Feibiao and securities affairs representative Dai Yiyi attending to answer investor questions [1] - The A-share market has reached a total market value of over 116 trillion yuan, marking a significant milestone one year after the "9.24" event [1] - The article highlights four major transformations that are reshaping the new ecology of China's capital market [1]

Group 1: Pharmaceutical Business - The pharmaceutical business showed significant growth in the first half of the year, primarily due to concentrated shipments. The company continues to adhere to a major client strategy, focusing on CDMO business models and has established stable commercial relationships with several leading global pharmaceutical companies [1] - The company is actively expanding its client base, targeting strategic and high-viscosity clients, which is expected to drive further growth in the pharmaceutical sector as client product pipelines develop [1] Group 2: Agricultural Protection Business - The agricultural protection business is anticipated to recover in the second half of the year as the client inventory reduction cycle comes to an end. The business primarily focuses on CDMO, covering a range of products including insecticides, herbicides, and fungicides [1] - The company has over 20 years of experience in the agricultural protection industry and is recognized as a strategic partner by five major original research agricultural protection companies, providing comprehensive R&D, production, and supply chain solutions [1] Group 3: Overseas Subsidiaries - The UK subsidiary has improved its operational performance in the first half of the year, with increased capacity utilization and significant foreign exchange gains contributing to its revenue performance [2] - The Malaysian subsidiary is still under construction, with plans for it to focus on the production and sales of patented agricultural protection products once operational [2] Group 4: New Energy Business - The new energy business is expected to achieve significant progress this year, with collaborations established with several leading new energy companies, leading to stable supply and a substantial revenue breakthrough anticipated [2] - The company aims to optimize production and sales processes to reduce costs and enhance profitability in the new energy sector while also focusing on innovative product development [2] Group 5: Competitive Landscape - The company believes that Indian competitors cannot fully replace domestic suppliers, as clients seek to stabilize their supply chains through multi-regional sourcing [2] - China maintains a more comprehensive supply chain system, mature waste management processes, and a robust patent protection system, which provides a competitive edge in the international market [2]

Group 1 - The core viewpoint of the article highlights the production capacity and market dynamics of lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide, indicating that companies are facing limited output due to market conditions [2][4] - Lianhua Technology has a planned production capacity of 20,000 tons/year for lithium hexafluorophosphate and 10,000 tons/year for lithium bis(fluorosulfonyl)imide, with strategic partnerships formed with leading domestic and international manufacturers to provide customized products [2] - Tianji Co., Ltd. reports that all three of its lithium hexafluorophosphate plants are operating at full capacity, with low inventory levels and rising prices, and expects continued full production in the second half of the year [4] Group 2 - The article mentions that Tianji Co., Ltd. currently has a production capacity of 37,000 tons/year for lithium hexafluorophosphate [4] - The meeting details indicate that the event is organized by Xinluo Information and will take place in Shanghai on November 12-13, 2025 [5][6] - The company emphasizes the importance of strategic cooperation and the development of competitive chemical products to support customer growth [2]

Core Viewpoint - The company has established itself as a significant strategic supplier in the agricultural protection industry, ranking among the top five companies [1] Group 1: Strategic Partnerships - The company has successfully become a strategic supplier for several international pharmaceutical giants and has partnered with many of the top 20 pharmaceutical companies [1] - This recognition has provided the company with a competitive product advantage and broad market opportunities [1] Group 2: Business Segments - The company's functional chemicals division primarily focuses on self-produced and self-sold products [1] - Key areas covered by this division include personal care and battery sectors [1]

Core Viewpoint - Lianhua Technology's stock price has experienced significant fluctuations, with a year-to-date increase of 90.53% but a recent decline in the last five trading days by 6.52% [2] Company Overview - Lianhua Technology, established on September 14, 1998, and listed on June 19, 2008, is located in Taizhou, Zhejiang Province. The company operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals [2] - The revenue composition of Lianhua Technology is as follows: pesticides 54.03%, pharmaceuticals 32.32%, functional chemicals 8.42%, equipment and engineering services 4.88%, and others 0.36% [2] Financial Performance - For the first half of 2025, Lianhua Technology reported revenue of 3.15 billion yuan, a year-on-year increase of 5.76%, and a net profit attributable to shareholders of 224 million yuan, reflecting a substantial growth of 1481.94% [3] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed over the past three years [4] Shareholder Information - As of June 30, 2025, Lianhua Technology had 72,300 shareholders, an increase of 88.92% from the previous period, with an average of 12,533 circulating shares per shareholder, a decrease of 47.07% [3] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 40.36 million shares, which is an increase of 21.34 million shares from the previous period [4] Market Activity - On September 23, Lianhua Technology's stock price fell by 2.06%, trading at 10.46 yuan per share, with a total transaction volume of 67.35 million yuan and a turnover rate of 0.70% [1] - The stock has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on June 25, where it recorded a net buy of -46.85 million yuan [2]

Core Viewpoint - Jinhua New Materials is set to be listed on the Beijing Stock Exchange with an IPO price of 18.15 CNY per share, aiming to raise 63.105 million CNY for various projects, including a high-end coupling agent project that will significantly increase production capacity [2][4]. Project Summaries - The IPO will raise funds for three main projects: - 60kt/a high-end coupling agent project with an investment of 50689.75 thousand CNY, which will add 30,000 tons/year of silane coupling agent capacity and 30,000 tons/year of functional silane intermediate capacity [2][3]. - 500 tons/year JH-2 pilot project with an investment of 3058.18 thousand CNY, aimed at developing hydroxylamine aqueous solution for use in chip manufacturing and special fiber production [2][3]. - Ketoxime industry chain smart factory construction project with an investment of 6310.50 thousand CNY [2][3]. Company Overview - Jinhua New Materials, established in December 2007, is a leading domestic enterprise in silane crosslinking agents and hydroxylamine salts, recognized as a national-level "little giant" enterprise [4]. - The company is state-owned, with the chemical giant Juhua Group as the largest shareholder, holding 82.49% of the shares [4]. - Major clients include Bayer, Bruntag, and several listed companies such as Wanhua Chemical and Xin'an Chemical [4]. Financial Performance - Projected revenues for Jinhua New Materials from 2022 to 2025 are as follows: - 2022: 994 million CNY - 2023: 1.115 billion CNY - 2024: 1.239 billion CNY - 2025: 1.063 billion CNY (a decrease of 14.25% year-on-year) [4]. - Net profits for the same period are projected as: - 2022: 79.592 million CNY - 2023: 173 million CNY - 2024: 211 million CNY - 2025: 199 million CNY (a decrease of 5.47% year-on-year) [4]. Market Position - Silane crosslinking agents are expected to generate 714 million CNY in revenue in 2024, accounting for 57.9% of total revenue, with a domestic market share of 38.16% [5]. - Hydroxylamine salts are projected to bring in 368 million CNY in revenue in 2024, representing 30% of total revenue, with a domestic market share of 42.37% [5]. - The company has a competitive position in the hydroxylamine salt market, with significant production capacity compared to other domestic players [5].